GlassScriptPhysician profile
Amanda Catherine Reed
NPI 1689025371
$1,522.27
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.23 · 2022: $578 · 2023: $410 · 2024: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $431.57 | 2022-2024 | |
| Pfizer INC. | $318.35 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $173.64 | 2022-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $151.92 | 2022-2024 | Xarelto |
| Abbvie INC. | $99.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.01 | 2022-2023 | Eliquis, Camzyos |
| Cvrx, INC. | $61.24 | 2022 | |
| Genzyme Corporation | $58.38 | 2023-2024 | |
| Baxter Healthcare | $53.23 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lantheus Medical Imaging, INC. | $39.71 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $27.66 | 2024 | Uptravi |
| Lexicon Pharmaceuticals, INC. | $21.82 | 2023 | Inpefa |
| Bardy Diagnostics, INC. | $16.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.